Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on X about a recent paper by Matthew Galsky et al.:
“Adjuvant nivolumab in MIUC. Checkmate 274. OS DATA. In ITT and PdL1 more than or equal to 1 %. Curves looks impressive.”
Authors: Matthew Galsky, Johannes Witjes, Jürgen Gschwend, Lynne Brophy, Dean Bajorin et al.
More posts featuring Amol Akhade.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.
He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant.
